Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 432-436

  Vegt, Erik ^a   Wetzels, Jack F M ^a   Russel, Frans G M ^b   Masereeuw, Rosalinde ^b   Boerman, Otto C ^a   Van Eerd, Juliette E ^a   Corstens, Frans H M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Kidneys; Radiolabeled octreotide; Succinylated gelatin

Indexed keywords

GELATIN SUCCINATE; HETASTARCH; PENTETREOTIDE; PENTETREOTIDE IN 111; SODIUM CHLORIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GELATIN; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; RADIOPROTECTIVE AGENT; SUCCINIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; DRUG UPTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; KIDNEY SCINTISCANNING; KIDNEY TUBULE ABSORPTION; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIATION DOSE; URINALYSIS; ANTIBODY SPECIFICITY; BODY BURDEN; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; RADIATION INJURY; SCINTISCANNING;

BODY BURDEN; DRUG COMBINATIONS; FEMALE; GELATIN; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OCTREOTIDE; ORGAN SPECIFICITY; RADIATION DOSAGE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOPHARMACEUTICALS; SUCCINATES;

EID: 33645960714     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
2. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)- octreotide and (177)Lu-DOTA(0),Tyr(3)-octreotate. J Nucl Med. 2005;46(suppl 1):83S-91S.
3. Valkema R, de Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122.
4. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
5. Barone R, Van Der Smissen P, Devuyst O, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int. 2005;67:969-976.
6. 111In-DTPA-octreotide. J Nucl Med. 2005;46:1696-1700.
7. 86Y-DOTA(0)-D-Phe1-Tyr3- octreotide (SMT487): a phase 1 clinical study - pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
8. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15.
9. Racusen LC, Finn WF, Whelton A, Solez K. Mechanisms of lysine-induced acute renal failure in rats. Kidney Int. 1985;27:517-522.
10. Racusen LC, Whelton A, Solez K. Effects of lysine and other amino acids on kidney structure and function in the rat. Am J Pathol. 1985;120:436-442.
11. Veldman BA, Schepkens HL, Vervoort G, Klasen I, Wetzels JF. Low concentrations of intravenous polygelines promote low-molecular weight proteinuria. Eur J Clin Invest. 2003;33:962-968.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
13. Buijs WC, Siegel JA, Boerman OC, Corstens FH. Absolute organ activity estimated by five different methods of background correction. J Nucl Med. 1998;39:2167-2172.
14. De Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388-1392.
15. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825-3834.
16. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591-2610.
17. Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med. 1996;37:829-833.
18. Barone R, Pauwels S, de Camps CJ, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19:2275-2281.
19. 111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
20. Maecke HR. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop. 2005;49:43-72.
21. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-1392.
22. 90Y-labelled analogue. Eur J Nucl Med. 1999;26:358-366.